Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours by Mir, Olivier, Azaro, Analia, Merchan, Jaime, Chugh, Rashmi, Trent, Jonathan, Rodon, Jordi, Ohnmacht, Ute, Diener, J.T., Smith, Claire, Yuen, Eunice, Oakley, Gerard Joseph, Le Cesne, Axel, Soria, Jean-Charles, Benhadji, Karim A., Massard, Christophe

Get full text

Abstract CT048: Population pharmacokinetics and pharmacodynamics for an oral Notch inhibitor, LY3039478, in the first-in-man study by Yuen, Eunice, Patel, Bharvin, Smith, Claire, Posada, Maria, Bell, Robert, Ohnmacht, Ute, Massard, Christophe, Rodon, Jordi, Benhadji, Karim

Get full text

Preclinical analyses and phase I evaluation of LY2603618 administered in combination with Pemetrexed and cisplatin in patients with advanced cancer by Calvo, Emiliano, Chen, Victor J., Marshall, Mark, Ohnmacht, Ute, Hynes, Scott M., Kumm, Elizabeth, Diaz, H. Bruce, Barnard, Darlene, Merzoug, Farhana F., Huber, Lysiane, Kays, Lisa, Iversen, Philip, Calles, Antonio, Voss, Beatrice, Lin, Aimee Bence, Dickgreber, Nicolas, Wehler, Thomas, Sebastian, Martin

Get full text

A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer by Azaro, Analia, Rodon, Jordi, Calles, Antonio, Braña, Irene, Hidalgo, Manuel, Lopez-Casas, Pedro P., Munoz, Manuel, Westwood, Paul, Miller, Joel, Moser, Brian A., Ohnmacht, Ute, Bumgardner, William, Benhadji, Karim A., Calvo, Emiliano

Get full text

Promoter methylation of RASSF1A, RARβ and DAPK predict poor prognosis of patients with malignant mesothelioma by Fischer, Jürgen R., Ohnmacht, Ute, Rieger, Norman, Zemaitis, Marius, Stoffregen, Clemens, Kostrzewa, Michael, Buchholz, Erika, Manegold, Christian, Lahm, Harald

Get full text

Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine by Fischer, Jürgen R, Ohnmacht, Ute, Rieger, Norman, Zemaitis, Marius, Stoffregen, Clemens, Manegold, Christian, Lahm, Harald

Get full text

Phase-I-study of four different schedules of pemetrexed, gemcitabine and cisplatin in patients with locally advanced or metastatic solid tumours by Hanauske, Axel-R, Endler, Corinna, Graefe, Tobias, Fleeth, Jochen, Scheel, Jobst von, Lüdtke, Frank E, Müller-Hagen, Sigrun, Depenbrock, Henrik, Ohnmacht, Ute, Bolling, Claus

Get full text

Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma by Fischer, Jürgen R, Ohnmacht, Ute, Rieger, Norman, Zemaitis, Marius, Stoffregen, Clemens, Kostrzewa, Michael, Buchholz, Erika, Manegold, Christian, Lahm, Harald

Get full text

Gemcitabine plus dose-escalated epirubicin in advanced breast cancer : results of a phase I study by LÜFTNER, D, FLATH, B, AKRIVAKIS, C, MERGENTHALER, H.-G, OHNMACHT, U, ARNING, M, POSSINGER, K

Get full text